UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 8,774 Shares of Iradimed Corporation (NASDAQ:IRMD)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Iradimed Corporation (NASDAQ:IRMD - Free Report) by 91.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,359 shares of the medical equipment provider's stock after purchasing an additional 8,774 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.14% of Iradimed worth $1,010,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. US Bancorp DE raised its stake in shares of Iradimed by 476.6% in the fourth quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock worth $34,000 after purchasing an additional 510 shares during the last quarter. Huntington National Bank boosted its position in shares of Iradimed by 34.0% during the fourth quarter. Huntington National Bank now owns 1,993 shares of the medical equipment provider's stock valued at $110,000 after buying an additional 506 shares during the last quarter. State of Wyoming bought a new stake in Iradimed during the fourth quarter worth $149,000. Avantax Advisory Services Inc. bought a new stake in Iradimed during the fourth quarter worth $217,000. Finally, Bessemer Group Inc. raised its position in Iradimed by 9.6% in the 4th quarter. Bessemer Group Inc. now owns 4,143 shares of the medical equipment provider's stock valued at $228,000 after buying an additional 362 shares during the last quarter. 92.34% of the stock is currently owned by institutional investors.

Iradimed Stock Performance

Shares of Iradimed stock traded down $0.38 during mid-day trading on Thursday, hitting $59.63. 3,907 shares of the stock were exchanged, compared to its average volume of 42,998. The company has a 50-day simple moving average of $53.61 and a 200 day simple moving average of $54.80. The company has a market capitalization of $758.20 million, a P/E ratio of 39.75 and a beta of 0.92. Iradimed Corporation has a 12 month low of $42.11 and a 12 month high of $63.29.

Iradimed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Tuesday, May 20th were issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date of this dividend was Tuesday, May 20th. Iradimed's dividend payout ratio (DPR) is currently 43.87%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on IRMD shares. Wall Street Zen raised shares of Iradimed from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th. Roth Mkm reissued a "buy" rating and set a $72.00 price target (up from $60.00) on shares of Iradimed in a research report on Friday, February 14th.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.